血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值

doi:10.6040/j.issn.1671-7554.0.2025.0015

摘要/Abstract

摘要： 目的探讨血清信号转导和转录激活因子5B(transducer and activator of transcription 5b, STAT5B)、NKAIN1 mRNA联合检测在乳腺癌(breast cancer, BC)诊断、分化程度及预后评估中的应用价值。方法选取2020年6月1日至2021年6月1日聊城市人民医院收治的80例经病理学确诊的BC患者为BC组,其中低分化组22例、中分化组25例和高分化组33例。乳腺良性病变患者80例为对照组。实时荧光定量聚合酶链式反应(quantitative polymerase chain reaction, qRT-PCR)检测血清STAT5B mRNA和NKAIN1 mRNA水平。对所有BC患者出院进行为期3年的随访,预后不良组(局部复发,远处转移,死亡)24例,预后良好组56例。ROC曲线分析血清STAT5B mRNA、NKAIN1 mRNA联合检测在BC诊断以及预后评估中的临床价值。采用SPSS 22.0软件进行数据统计分析。结果与对照组相比,BC组患者雌二醇、睾酮、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)水平显著升高(P<0.05),血清中STAT5B mRNA和NKAIN1 mRNA水平显著升高(P<0.05)。与低分化组相比,中分化组和高分化组患者血清中STAT5B mRNA和NKAIN1 mRNA水平依次显著降低(P<0.05)。与预后良好组相比,预后不良组患者血清中STAT5B mRNA和NKAIN1 mRNA水平显著升高(P<0.05)。ROC结果显示,血清STAT5B mRNA、NKAIN1 mRNA联合诊断BC的AUC高于STAT5B mRNA(Z=3.015,P=0.003)、NKAIN1 mRNA(Z=2.919,P=0.004)单独诊断的AUC。血清STAT5B mRNA、NKAIN1 mRNA联合预测BC患者预后的AUC高于STAT5B mRNA(Z=4.305,P<0.001)、NKAIN1 mRNA(Z=3.307,P=0.001)单独预测的AUC。结论应用血清STAT5B、NKAIN1 mRNA可以提高乳腺癌诊断的敏感性,更准确地预测乳腺癌预后,对于乳腺癌的诊断及预后评估有重要意义。

关键词: 信号转导和转录激活因子5B, NKAIN1, 乳腺癌, 诊断, 分化程度, 预后

Abstract: Objective To explore the value of combined detection of serum signal transducer and activator of transcription 5b(STAT5B)and NKAIN1 mRNA in the diagnosis, differentiation and prognosis evaluation of breast cancer(BC). Methods Eighty patients with pathologically confirmed BC admitted to Liaocheng Peoples Hospital from, 2020 to June 1, 2021 were selected as the BC group, of which 22 cases were in the low-differentiation group, June 1, 25 cases were in the middle-differentiation group, and 33 cases were in the high-differentiation group. The 80 patients with benign breast lesions were the control group. Serum STAT5B mRNA and NKAIN1 mRNA levels were detected by real-time fluorescence quantitative polymerase chain reaction(qRT-PCR). All BC patients were discharged from the hospital for a 3-year follow-up, with 24 cases in the poor prognosis group(local recurrence, distant metastasis, and death)and 56 cases in the good prognosis group. ROC curves were used to analyze the clinical value of the combined detection of serum STAT5B mRNA and NKAIN1 mRNA in the diagnosis of BC as well as in prognostic assessment. SPSS 22.0 software was used for statistical analysis of data. Results Compared with the control group, patients in the BC group had significantly higher levels of estradiol, testosterone, and low-density lipoprotein cholesterol(LDL-C)(P<0.05), and significantly higher levels of STAT5B mRNA and NKAIN1 mRNA in serum(P<0.05). Compared with the low-differentiation group, the serum levels of STAT5B mRNA and NKAIN1 mRNA were significantly lower in the middle-differentiation group and the high-differentiation group patients in that order(P<0.05). The serum levels of STAT5B mRNA and NKAIN1 mRNA were significantly higher in patients in the poor prognosis group compared with those in the good prognosis group(P<0.05). The ROC results showed that the AUC of serum STAT5B mRNA and NKAIN1 mRNA combined to diagnose BC was higher than that of STAT5B mRNA(Z=3.015, P=0.003), NKAIN1 mRNA(Z=2.919, P=0.004)AUC for diagnosis alone. Serum STAT5B mRNA, NKAIN1 mRNA combined predicted prognosis of BC patients with higher AUC than STAT5B mRNA(Z=4.305, P<0.001), NKAIN1 mRNA(Z=3.307, P=0.001)AUC predicted alone. Conclusion The application of serum STAT5B and NKAIN1 mRNA can improve the sensitivity of BC diagnosis and predict the prognosis of BC more accurately, which is important for the diagnosis and prognosis evaluation of BC.

Key words: Signal transducer and activator of transcription 5b, NKAIN1, Breast cancer, Diagnosis, Degree of differen-tiation, Prognosis

中图分类号:

R737.9

刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.

LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer[J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.

参考文献

[1] Giaquinto AN, Sung H, Newman LA, et al. Breast cancer statistics 2024[J]. CA A Cancer J Clinicians, 2024, 74(6): 477-495.
[2] 韩佳雯, 苏婷婷, 徐元兵, 等. 肿瘤浸润淋巴细胞在三阴性乳腺癌新辅助化疗预测价值中的研究进展[J]. 中国肿瘤临床, 2023, 50(19): 1011-1016. HAN Jiawen, SU Tingting, XU Yuanbing, et al. Research progress of tumor infiltrating lymphocytes in predicting the efficacy of neo-adjuvant chemotherapy for triple negative breast cancer[J]. Chinese Journal of Clinical Oncology, 2023, 50(19): 1011-1016.
[3] 范蕾, 黄纪程, 李尧, 等. 老年与非老年女性乳腺癌患者临床病理特征和影响预后因素的差异分析[J]. 中华老年医学杂志, 2024, 43(9): 1162-1173. FAN Lei, HUANG Jicheng, LI Yao, et al. Analysis of differences in clinicopathological characteristics and prognostic factors between elderly and non-elderly female breast cancer patients[J]. Chinese Journal of Geriatrics, 2024, 43(09): 1162-1173.
[4] Katsura C, Ogunmwonyi I, Kankam HK, et al. Breast cancer: presentation, investigation and management[J]. Br J Hosp Med, 2022, 83(2): 1-7.
[5] Herrera-Quintana L, Vázquez-Lorente H, Plaza-Diaz J. Breast cancer: extracellular matrix and microbiome interactions[J]. Int J Mol Sci, 2024, 25(13): 7226. doi:10.3390/ijms25137226
[6] 刘颖, 董苑, 陈诚. 数字乳腺断层X线摄影与超声光散射断层成像诊断早期乳腺癌的对比研究[J]. 中国医学影像学杂志, 2022, 30(6): 570-574. LIU Ying,DONG Yuan,CHEN Cheng. Digital breast tomosynthesis and optical tomography image ultrasongraphy in the diagnosis of early breast cancer: a comparative study[J].Chinese Journal of Medical Imaging, 2022, 30(6): 570-574.
[7] 梁霄, 李娅兰, 白皓天, 等. 基于生物信息学的乳腺癌关键基因筛选及实验验证[J]. 海南医学院学报, 2023, 29(1): 51-62,71. LIANG Xiao, LI Yalan, BAI Haotian, et al. Bioinformatics screening of breast cancer related genes and potential drug research[J]. Journal of Hainan Medical University, 2023, 29(1): 51-62,71.
[8] 王爽, 贾凯超, 刘俊田. 探究luminal型乳腺癌早期诊断及预后相关microRNA的生物学功能及应用价值分析[J]. 肿瘤, 2022, 42(5): 334-344. WANG Shuang, JIA Kaichao, LIU Juntian. Exploring the biological function and application value of early diagnosis and prognosis-related microRNAs of luminal breast cancer[J]. Tumor, 2022, 42(5): 334-344.
[9] 何英, 石先伟, 张雪琳, 等. 乳腺癌组织miR-216b-5p、miR-589-5p与肿瘤恶性增殖基因表达和预后的关系[J]. 检验医学与临床, 2025, 22(8): 1116-1120+1126. HE Ying, SHI Xianwei, ZHANG Xuelin, et al. Relationship between miR-216b-5p,miR-589-5p and tumor malignant proliferation gene expression and prognosis in breast cancer tissues[J]. Laboratory Medicine and Clinic, 2025, 22(8): 1116-1120+1126.
[10] Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments[J]. Signal Transduct Target Ther, 2025, 10(1): 49. doi:10.1038/s41392-024-02108-4
[11] 王浩, 李南林, 曹海玲. 循环肿瘤细胞与三阴性乳腺癌预后及肿瘤状态的关系分析[J]. 实用临床医药杂志, 2023, 27(18): 39-43. WANG Hao, LI Nanlin, CAO Hailing. Relationships of circulating tumor cells with prognosis and tumor status of triple-negative breast cancer[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 39-43.
[12] 匡思杰, 成宏, 孙敬杰. ACCN3和PXDNL对乳腺癌细胞增殖、侵袭、迁移和患者生存预后的影响[J]. 重庆医学, 2023, 52(9): 1399-1407. KUANG Sijie, CHENG Hong, SUN Jingjie. Effects of ACCN3 and PXDNL on the proliferation, invasion and migration of breast cancer cell lines and the survival and prognosis of patients[J]. Chongqing Medicine, 2023, 52(9): 1399-1407.
[13] 陈晶晶, 李玉凤, 石鹏, 等. 外周血circRNA_001569、circRNA CDR1as对三阴性乳腺癌新辅助化疗敏感性的预测作用[J]. 中国老年学杂志, 2025, 45(6): 1302-1306. CHEN Jingjing, LI Yufeng, SHI Peng, et al. Prediction effect of circRNA_001569 and circRNA CDR1as in peripheral blood on neoadjuvant chemotherapy sensitivity of triple-negative breast cancer[J]. Chinese Journal of Gerontology, 2025, 45(6): 1302-1306.
[14] Li JY, Li L, Mahesutihan G, et al. Identification of STAT5B as a biomarker associated with prognosis and immune infiltration in breast cancer[J]. Medicine, 2023, 102(9): e32972. doi:10.1097/MD.0000000000032972
[15] Yang T, Chi YN, Wang XA, et al. PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling[J]. Cell Death Dis, 2024, 15(2): 128. doi: 10.1038/s41419-023-06362-2
[16] Wang XM, Yang FZ, Sun Z, et al. NKAIN1, as an oncogene, promotes the proliferation and metastasis of breast cancer, affecting its prognosis[J]. Mol Carcinog, 2024, 63(7): 1392-1405.
[17] 王翠翠, 孔繁菲, 马剑, 等. 基于TCGA数据库探讨NKAIN1表达增高与子宫内膜癌预后的关系[J]. 肿瘤预防与治疗, 2020, 33(5): 401-407. WANG Cuicui, KONG Fanfei, MA Jian, et al. Increased expression of NKAIN1 in endometrial carcinoma predicts poor prognosis: an analysis based on studies from TCGA datasets[J]. Journal of Cancer Control and Treatment, 2020, 33(5): 401-407. doi:10.3969/j.issn.1674-0904.2020.05.005
[18] 刘真, 袁洋, 江泽飞. 2024 CSCO指南晚期乳腺癌更新要点解读[J]. 中国肿瘤临床, 2024, 51(23):1223-1226. LIU Zhen, YUAN Yang, JIANG Zefei. Interpretation of the update points of 2024 CSCO guidelines for advanced breast cancer[J]. Chinese Journal of Clinical Oncology, 2024, 51(23):1223-1226.
[19] 宋鹤, 步鹏, 杜海艳, 等. 转录因子STAT5A, STAT5B在T淋巴母细胞淋巴瘤中的表达及临床意义[J]. 中国组织化学与细胞化学杂志, 2021, 30(3): 259-264. SONG He, BU Peng, DU Haiyan, et al. Expression of transcription factors STAT5A and STAT5B in T-cell lymphoblastic lymphoma and its clinical significance[J]. Chinese Journal of Histochemistry and Cytochemistry, 2021, 30(3): 259-264.
[20] Tremblay CS, Saw J, Boyle JA, et al. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia[J]. Blood, 2023, 142(3): 274-289.
[21] 郭强, 樊红琼, 高素君, 等. 伴STAT5b: RARα融合基因急性早幼粒细胞白血病1例并文献复习[J]. 白血病·淋巴瘤, 2024, 33(4): 224-227. GUO Qiang, FAN Hongqiong, GAO Sujun, et al. Acute promyelocytic leukemia with STAT5b: RARα fusion gene: report of 1 case and review of literature[J]. Journal of Leukemia and Lymphoma, 2024, 33(4): 224-227.
[22] Hou YG, Huang SY, Liu JC, et al. DOT1L promotes cell proliferation and invasion by epigenetically regulating STAT5B in renal cell carcinoma[J]. Am J Cancer Res, 2023, 13(1): 276-292.
[23] Erdogan F, Radu TB, Orlova A, et al. JAK-STAT core cancer pathway: an integrative cancer interactome analysis[J]. J Cell Mol Med, 2022, 26(7): 2049-2062.
[24] Cook MB, Thrift AP. Epidemiology of barretts esophagus and esophageal adenocarcinoma: implications for screening and surveillance[J]. Gastrointest Endosc Clin N Am, 2021, 31(1): 1-26.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed